C12N 2830/30
Being an enhancer not forming part of the promoter region
Official title: being an enhancer not forming part of the promoter region
C12N2830/30 (Being an enhancer not forming part of the promoter region) appears on 176 US grants and 153 published applications in this corpus.
Search patents in C12N- Granted patents
- 176
- Published applications
- 153
- Assignees
- 137
- Inventors
- 392
- Latest grant
- 30 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1992 | 2 | 0 |
| 1993 | 0 | 0 |
| 1994 | 3 | 0 |
| 1995 | 2 | 0 |
| 1996 | 13 | 0 |
| 1997 | 11 | 0 |
| 1998 | 15 | 0 |
| 1999 | 11 | 0 |
| 2000 | 10 | 0 |
| 2001 | 9 | 0 |
| 2002 | 9 | 12 |
| 2003 | 6 | 14 |
| 2004 | 5 | 13 |
| 2005 | 6 | 9 |
| 2006 | 2 | 6 |
| 2007 | 7 | 4 |
| 2008 | 4 | 2 |
| 2009 | 0 | 6 |
| 2010 | 7 | 4 |
| 2011 | 3 | 7 |
| 2012 | 3 | 1 |
| 2013 | 3 | 3 |
| 2014 | 4 | 5 |
| 2015 | 2 | 5 |
| 2016 | 3 | 4 |
| 2017 | 3 | 8 |
| 2018 | 7 | 10 |
| 2019 | 3 | 9 |
| 2020 | 5 | 5 |
| 2021 | 4 | 5 |
| 2022 | 3 | 6 |
| 2023 | 4 | 3 |
| 2024 | 1 | 4 |
| 2025 | 3 | 5 |
| 2026 | 3 | 3 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Mammalian expression vectors30 Jun 2026US 12,668,809 B2Biocon Biologics Limited
- Augmentations to lentiviral vectors (CCLC-MGATA/ANK-CORE LCR-BETA-AS3-FB) to increase expression26 May 2026US 12,637,696 B2The Regents of the University of California
- Globin gene therapy for treating hemoglobinopathies21 Apr 2026US 12,606,848 B2Memorial Sloan Kettering Cancer Center
- Integration of mesa receptors and promotors to implement customized cellular function28 Oct 2025US 12,454,689 B2Northwestern University
- Diet controlled expression of a nucleic acid encoding a pro-apoptotic protein23 Sep 2025US 12,419,971 B2Assistance Publique-Hopitaux de Paris
- Nucleic acid regulatory elements for constitutive gene expression and methods of use23 Apr 2026US 2026/0109978 A1Meiragtx UK II Limited
- Nucleic acid regulatory elements for gene expression in the liver and methods of use23 Apr 2026US 2026/0109979 A1Meiragtx UK II Limited
- Slc26a4 regulatory elements and uses thereof5 Feb 2026US 2026/0034248 A1Decibel Therapeutics, Inc.
- Tat-induced crispr/endonuclease-based gene editing7 Aug 2025US 2025/0250562 A1Temple University of the Commonwealth System of Higher Education
- Artificial expression constructs for modulating gene expression in the cerebellum and a secondary cell type24 Jul 2025US 2025/0235550 A1Allen Institute
Most cited
By later US patents
- Ransgenic non-human animals for producing heterologous antibodies1,941US 5,545,806 AGenPharm International, Inc. · 1996
- Transgenic non-human animals capable of producing heterologous antibodies1,680US 5,633,425 AGenPharm International, Inc. · 1997
- Transgenic non-human animals for producing heterologous antibodies1,604US 5,625,126 AGenPharm International, Inc. · 1997
- Transgenic non-human animals capable of producing heterologous antibodies950US 5,770,429 AGenPharm International, Inc. · 1998
- Transgenic non-human animals for producing heterologous antibodies679US 5,814,318 AGenPharm International, Inc. · 1998